$ATNM SEC Filings

Filed On	Filing
16 Oct 2026	Form 4: David Matthew T, Chief Financial Officer Received 250,000 shares as a grant or award · Granted 250,000 Stock Option (right to purchase)
16 Oct 2026	Form 3: David Matthew T, Chief Financial Officer No securities owned
16 Oct 2026	ARS
16 Oct 2026	Proxy statement: annual meeting on November 25, 2026 CEO pay $1.2M, up 1.2% · say-on-pay vote
15 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure NEW YORK, October 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., ...
09 Oct 2026	REGISTRATION STATEMENT
10 Sep 2026	Form 3: Heeger Steffen Wilhem, Chief Medical Officer Holds 153,868 shares of Common Stock
10 Sep 2026	Form 3: Kamal Adeela, Chief Scientific Officer Holds 213,648 shares of Common Stock
04 Sep 2026	Form 4: Nicholson, C. David, Director Received 62,800 shares as a grant or award · Granted 94,200 Stock Option (Right to Buy)
04 Sep 2026	Form 4: Shetty Ajit, Director Received 61,600 shares as a grant or award · Granted 92,400 Stock Option (Right to Buy)
04 Sep 2026	Form 4: Almenoff June Sherie, Director Received 18,000 shares as a grant or award · Granted 27,000 Stock Option (Right to Buy)
04 Sep 2026	Form 4: Seth Sandesh, Director Received 1,780,874 shares as a grant or award · Granted 1,130,400 Stock Option (Right to Buy)
04 Sep 2026	Form 4: Steinhart Richard I, Director Received 62,800 shares as a grant or award · Granted 94,200 Stock Option (Right to Buy)
04 Sep 2026	Form 4: Chell Jeffrey W., Director Received 61,600 shares as a grant or award · Granted 92,400 Stock Option (Right to Buy)
14 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
07 Aug 2026	QUARTERLY REPORT
18 Jun 2026	8-K: Other Events
29 May 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
08 May 2026	QUARTERLY REPORT
30 Mar 2026	ANNUAL REPORT

Comments